#1 Clinical Trials Search in Europe

Lisinopril Dihydrate

This article discusses a clinical trial investigating the use of Lisinopril Dihydrate, a medication commonly used to treat heart failure. The study aims to evaluate the effectiveness and safety of a new drug combination that includes Lisinopril Dihydrate for patients with heart failure. The trial focuses on finding the right dose and understanding how well the treatment works in reducing certain markers of heart failure.

Table of Contents

What is Lisinopril Dihydrate?

Lisinopril Dihydrate is a medication that belongs to a class of drugs called Angiotensin-Converting Enzyme (ACE) inhibitors[1]. It is commonly known by its shorter name, Lisinopril. This medication is widely used to treat various cardiovascular conditions and is available in tablet form for oral use[1].

How Does Lisinopril Work?

Lisinopril works by inhibiting the action of an enzyme called ACE (Angiotensin-Converting Enzyme). This enzyme is responsible for producing a substance in your body called angiotensin II, which causes blood vessels to narrow. By blocking this enzyme, Lisinopril helps to relax and widen blood vessels, making it easier for your heart to pump blood throughout your body[1].

What Conditions Does Lisinopril Treat?

Lisinopril is primarily used to treat several cardiovascular conditions, including:

  • Heart Failure: It helps improve symptoms and survival rates in patients with heart failure[1].
  • High Blood Pressure (Hypertension): Lisinopril is effective in lowering blood pressure[1].
  • After Heart Attack: It may be prescribed to improve survival chances after a heart attack[1].

How is Lisinopril Administered?

Lisinopril is typically taken orally in tablet form. The dosage and frequency of administration depend on the condition being treated and the individual patient’s response. It’s usually taken once daily, with or without food[1].

Recent Clinical Trials

A recent clinical trial (2023-504678-39-00) has been exploring the use of Lisinopril in combination with other medications for heart failure patients. This study aims to evaluate the efficacy of a new drug (XXB750) in patients with heart failure who are already on standard treatments, including ACE inhibitors like Lisinopril[1].

The trial includes patients with the following characteristics:

  • Adults aged 18 years or older
  • Diagnosed with heart failure, with symptoms classified as New York Heart Association (NYHA) class II-III
  • Left Ventricular Ejection Fraction (LVEF) less than 50%
  • Currently taking ACE inhibitors (like Lisinopril) or similar medications

This study highlights the ongoing research into improving heart failure treatments and the continued importance of medications like Lisinopril in managing cardiovascular conditions[1].

Potential Side Effects and Precautions

While Lisinopril is generally well-tolerated, it can cause side effects in some patients. Common side effects may include:

  • Dizziness
  • Headache
  • Cough
  • High potassium levels

It’s important to note that Lisinopril may not be suitable for everyone. Patients with a history of angioedema (severe swelling) should not take this medication. Additionally, your doctor will monitor your kidney function and potassium levels while you’re on Lisinopril[1].

Always consult with your healthcare provider before starting or changing any medication regimen.

Aspect Details
Study Type Multi-center, randomized, placebo- and active-controlled, parallel-group
Duration 24 weeks
Main Objective Evaluate efficacy and dose-response of XXB750 in reducing NT-proBNP
Participants Adults with heart failure symptoms, LVEF < 50%, specific NT-proBNP levels
Key Inclusion Criteria Age ≥ 18, NYHA class II-III, stable dose of heart failure medications
Key Exclusion Criteria Recent hospitalization for heart failure, very high/low blood pressure, severe kidney dysfunction
Primary Endpoint Change in log NT-proBNP from baseline to Week 16
Role of Lisinopril Dihydrate Part of standard heart failure treatment in combination with new drug

FAQ

  • What is the main goal of this clinical trial? The main goal is to evaluate the effectiveness of different doses of a new drug combination (including Lisinopril Dihydrate) compared to a placebo in reducing a specific heart failure marker called NT-proBNP in patients with heart failure.
  • Who can participate in this clinical trial? Participants must be 18 years or older, have symptoms of heart failure (NYHA class II-III), have a left ventricular ejection fraction (LVEF) less than 50%, and meet specific NT-proBNP levels. They should also be taking certain heart failure medications at stable doses.
  • How long does the clinical trial last? The trial lasts for 24 weeks (about 6 months), with the primary evaluation of the treatment's effectiveness occurring at 16 weeks.
  • What is Lisinopril Dihydrate's role in this study? Lisinopril Dihydrate is part of the standard heart failure treatment that participants will be receiving. The study aims to evaluate a new drug combination that includes this medication to see if it can improve outcomes for heart failure patients.
  • Are there any specific exclusion criteria for the trial? Yes, people with recent hospitalization for heart failure, very high or low blood pressure, inability to tolerate certain medications, high potassium levels, severely reduced kidney function, or a history of angioedema cannot participate in the trial.

Ongoing Clinical Trials on Lisinopril Dihydrate

  • Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study on Preventing Heart Disease in Diabetes Patients Using Eprosartan Mesilate and Drug Combination

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Austria Spain

  • Study of XXB750 and Drug Combination for Patients with Heart Failure

    Not recruiting

    1 1
    Investigated drugs:
    Bulgaria Czechia Denmark France Germany Hungary +5

Glossary

  • NT-proBNP: N-terminal prohormone B-type natriuretic peptide, a substance in the blood that increases when heart failure worsens. It's used to diagnose and monitor heart failure.
  • LVEF: Left Ventricular Ejection Fraction, a measurement of how much blood the left ventricle pumps out with each contraction. It's used to determine how well the heart is functioning.
  • NYHA class: New York Heart Association classification, a system used to classify the severity of heart failure symptoms.
  • Placebo: A substance that has no active ingredients and is used as a control in clinical trials to test the effectiveness of a drug.
  • ACEI: Angiotensin-Converting Enzyme Inhibitor, a type of medication used to treat high blood pressure and heart failure.
  • ARB: Angiotensin Receptor Blocker, another type of medication used to treat high blood pressure and heart failure.
  • eGFR: Estimated Glomerular Filtration Rate, a test used to check how well the kidneys are working.
  • Angioedema: A swelling under the skin that can occur as a side effect of certain medications.

References

  1. http://clinicaltrials.eu/trial/study-of-xxb750-and-drug-combination-for-patients-with-heart-failure/